Sign in →

Test ID VZM Varicella-Zoster Virus (VZV) Antibody, IgM, Serum

Useful For

Diagnosing acute-phase infection with varicella-zoster virus

Method Name

Immunofluorescence Assay (IFA)

Reporting Name

Varicella-Zoster Ab, IgM, S

Specimen Type

Serum

Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.5 mL

Specimen Minimum Volume

0.2 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 14 days
  Frozen  14 days

Clinical Information

Varicella-zoster virus (VZV), a herpes virus, causes 2 exanthematous (rash-associated) diseases, chickenpox and herpes zoster (shingles). Chickenpox is a highly contagious disease usually contracted during childhood and is characterized by a dermal vesiculopustular rash that develops in successive crops. Although primary infection results in immunity to subsequent exposure to chickenpox, the virus remains latent in the body, localized to the dorsal root or cranial nerve ganglia. Reactivation of latent infection manifests as herpes zoster. On reactivation, the virus migrates along neural pathways to the skin, producing a unilateral rash usually limited to a single dermatome. Reactivation occurs in older adults and in patients with impaired cellular immunity.

 

Several populations are at risk of suffering unusually severe reactions to VZV infections. The infection in pregnant women may spread through the placenta to the fetus, causing congenital disease in the infant. Immunocompromised patients in hospitals may contract severe nosocomial infections from others who have active VZV infections. Therefore, serologic screening of direct health care providers (physicians, allied health care personnel) and individuals in high-risk groups is necessary to avoid uncontrolled spread of infection.

 

While the clinical presentation of VZV infection is generally characteristic, serologic evaluation of patients with atypical and systemic infections is often required. For example, it is extremely important to serologically evaluate patients for the early detection of VZV infections in hospital settings. Nosocomial spread of VZV infection can be life-threatening to immunocompromised patients susceptible to infection.

Reference Values

Negative (reported as positive or negative)

Cautions

The performance characteristics with individuals vaccinated with varicella-zoster virus (OKA strain) have not been established.

 

The test must be performed on serum. The use of whole blood, plasma, or cord blood has not been established.

 

Positive results from cord blood or neonates should be interpreted with caution.

 

Results from immunocompromised patients should be interpreted with caution.

Day(s) Performed

Monday through Friday; 9 a.m. and 3 p.m., Saturday, Sunday; Varies

Report Available

Same day/1 day

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86787

NY State Approved

Yes